Thibault Mazard

13PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 21, 2025
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study.

Jean-Frédéric Blanc, Mohamed Bouattour, Ludovic Gauthier

|Jun 20, 2025
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.

Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou

|Jul 27, 2024
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?

Auriane de Pellegars-Malhortie, Laurence Picque Lasorsa, Thibault Mazard

|Jul 10, 2024
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.

Antoine Adenis, François Ghiringhelli, Ludovic Gauthier

|Jun 17, 2024
Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.

Thibault Mazard, Caroline Mollevi, Evelyne M Loyer

|Feb 11, 2023
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study.

Karl Bordeau, Morgan Michalet, Aïcha Keskes

Pageof 3

Frequent Collaborators

2 joint publications

Eric Assenat

2 joint publications

Thierry André

2 joint publications

Antoine Adenis

2 joint publications

Marc Ychou